Drug Profile
Research programme: mucopolysaccharidosis IVA therapy - Vivendy Therapeutics
Alternative Names: GALNS - Vivendy TherapeuticsLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Saint Louis University
- Developer Vivendy Therapeutics
- Class Chondroitinsulfatases
- Mechanism of Action GALNS protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Mucopolysaccharidosis IV
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Mucopolysaccharidosis-IV in Switzerland (Parenteral)